Originally published In Press as doi:10.1074/mcp.R600010-MCP200 on May 29, 2006.
Molecular & Cellular Proteomics 5:1745-1759, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.
Cancer
Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer*
Carlos A. Casiano , ,¶,
Melanie Mediavilla-Varela and
Eng M. Tan||
From the Center for Health Disparities Research and Department of Biochemistry and Microbiology and Department of Medicine, Loma Linda University School of Medicine, Loma Linda, California 92350 and the || W. M. Keck Autoimmune Disease Center, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037
The recognition that human tumors stimulate the production of autoantibodies against autologous cellular proteins called tumor-associated antigens (TAAs) has opened the door to the possibility that autoantibodies could be exploited as serological tools for the early diagnosis and management of cancer. Cancer-associated autoantibodies are often driven by intracellular proteins that are mutated, modified, or aberrantly expressed in tumor cells and hence are regarded as immunological reporters that could help uncover molecular events underlying tumorigenesis. Emerging evidence suggests that each type of cancer might trigger unique autoantibody signatures that reflect the nature of the malignant process in the affected organ. The advent of novel genomic, proteomic, and high throughput approaches has accelerated interest in the serum autoantibody repertoire in human cancers for the discovery of candidate TAAs. The use of individual anti-TAA autoantibodies as diagnostic or prognostic tools has been tempered by their low frequency and heterogeneity in most human cancers. However, TAA arrays comprising several antigens significantly increase this frequency and hold great promise for the early detection of cancer, monitoring cancer progression, guiding individualized therapeutic interventions, and identification of novel therapeutic targets. Our recent studies suggest that the implementation of TAA arrays in screening programs for the diagnosis of prostate cancer and other cancers should be preceded by the optimization of their sensitivity and specificity through the careful selection of the most favorable combinations of TAAs.
¶ To whom correspondence should be addressed. Tel.: 909-558-1000 (ext. 42759); Fax: 909-558-0177; E-mail: ccasiano{at}llu.edu

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G Kijanka, S Hector, E W Kay, F Murray, R Cummins, D Murphy, B D MacCraith, J H M Prehn, and D Kenny
Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer
Gut,
January 1, 2010;
59(01):
69 - 78.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Desmetz, C. Bascoul-Mollevi, P. Rochaix, P.-J. Lamy, A. Kramar, P. Rouanet, T. Maudelonde, A. Mange, and J. Solassol
Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women
Clin. Cancer Res.,
July 15, 2009;
15(14):
4733 - 4741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kanojia, M. Garg, S. Gupta, A. Gupta, and A. Suri
Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer
Cancer Epidemiol. Biomarkers Prev.,
February 1, 2009;
18(2):
630 - 639.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|